Cue Biopharma's Ray Sumita sells 1,844 shares

The Chief Legal Compliance Officer’s shares were sold automatically under Cue Biopharma’s company-wide policy to meet mandatory tax withholding, not at the officer’s discretion.

Rhea-AI Filing Summary

Cue Biopharma, Inc. Chief Legal Compliance Officer and Corporate Secretary Ray Sumita reported a sale of 1,844 shares of common stock on October 12, 2026, at $28.05 per share. The shares were sold automatically under the issuer’s Company-Wide Policy to satisfy mandatory tax withholding through a sell-to-cover transaction; the sale was not discretionary, and Sumita did not control its timing, price, or share count. The sale was connected with restricted stock unit vesting and settlement. Sumita directly held 116,701 shares after the transaction. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 1,844 shares

Net Sell 1 txn

Insider Ray Sumita

Role Chief Legal Compliance Officer

Sold 1,844 shs ($52K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,844	$28.05	$52K

Holdings After Transaction: Common Stock — 116,701 shares (Direct)

Footnotes (1)

1. F1. The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.

Key Figures

Common stock sold: 1,844 shares Sale price: $28.05 per share Direct shares held after sale: 116,701 shares

3 metrics

Common stock sold 1,844 shares October 12, 2026

Sale price $28.05 per share October 12, 2026

Direct shares held after sale 116,701 shares After the October 12, 2026 sale

Key Terms

sell-to-cover, restricted stock units, vesting and settlement

3 terms

sell-to-cover financial

"through a sell-to-cover transaction"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"restricted stock unit vesting and settlement"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting and settlement technical

"restricted stock unit vesting and settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CUE shares did Ray Sumita sell?

Ray Sumita, Cue Biopharma’s Chief Legal Compliance Officer and Corporate Secretary, sold 1,844 shares of common stock on October 12, 2026, at $28.05 per share. Direct holdings after the sale were 116,701 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 09:40 PM EDT Accepted by SEC EDGAR 10/14/2026 - 09:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ray Sumita

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

100 CHESTNUT STREET, SUITE 300

(Street)

SOMERVILLE MASSACHUSETTS 02143

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Legal Compliance Officer		Corporate Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/12/2026		S(1)		1,844	D	$28.05	116,701	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.

	/s/ Sumita Ray	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)